All Stories

  1. Towards precision medicine in non-invasive brain stimulation for chronic pain
  2. Pharmacological and non-pharmacological treatments for impulsive-compulsive behaviors in Parkinson's disease
  3. Exploiting cortical and peripheral somatosensory stimulation for inducing sensorimotor plasticity in humans
  4. Are We Missing Something About the Maximum Dosing of Botulinum Toxin Type A1 in Adult and Pediatric Patients with Spasticity?
  5. Diagnostic Nerve Block to Guide Botulinum Neurotoxin Type A Injection for Clonus in Spastic Equinovarus Foot: A Retrospective Study
  6. Does the Diffusion Profile Differ Between Botulinum Toxin Type a Formulations? Implications for the Management of Post-Stroke Spasticity
  7. Medical technologies, telemedicine and artificial intelligence for neurotrauma and neurorehabilitation
  8. Biomarkers for cognitive impairment in alpha-synucleinopathies: an overview of systematic reviews and meta-analyses
  9. A window into the mind-brain-body interplay: Development of diagnostic, prognostic biomarkers, and rehabilitation strategies in functional motor disorders
  10. Do Diagnostic Nerve Blocks Affect the Starting Dose of Botulinum Neurotoxin Type A for Spasticity? A Case-Control Study
  11. Role of Diagnostic Nerve Blocks in the Goal-Oriented Treatment of Spasticity with Botulinum Toxin Type A: A Case–Control Study
  12. Autoimmune Movement Disorders Complicating Treatment with Immune Checkpoint Inhibitors
  13. A Low-Cost Wireless Body Area Network for Human Activity Recognition in Healthy Life and Medical Applications
  14. What’s New in Neuropathy?
  15. Exploring Outcome Priorities and Real-Life Management of Chemotherapy-Induced Peripheral Neurotoxicity: A Survey of the Italian Association for the Study of Pain members
  16. Pharmacological and non-pharmacological treatments for impulsive-compulsive behaviors in Parkinson's disease
  17. Effect of Upper Limb Motor Rehabilitation on Cognition in Parkinson’s Disease: An Observational Study
  18. Editorial: Advances and innovation in neurotrauma and neurorehabilitation
  19. Cerebellar involvement associated with immune checkpoint inhibitors: A systematic review
  20. IncobotulinumtoxinA Injection for Treating Children with Idiopathic Toe Walking: A Retrospective Efficacy and Safety Study
  21. Wearables, sensors, and smart devices for the detection and monitoring of chemotherapy‐induced peripheral neurotoxicity: Systematic review and directions for future research
  22. D2/D3 Receptor Agonism: Paving the Way for a New Therapeutic Target for Taste Disorders in Parkinson’s Disease and Other Conditions?
  23. Brain Structural and Functional Alterations in Multiple Sclerosis-Related Fatigue: A Systematic Review
  24. Pharmacological Treatment of Pain and Agitation in Severe Dementia and Responsiveness to Change of the Italian Mobilization–Observation–Behavior–Intensity–Dementia (I-MOBID2) Pain Scale: Study Protocol
  25. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: systematic review and evidence-based recommendations
  26. Combining Low-Dose Radiation Therapy and Magnetic Resonance Guided Focused Ultrasound to Reduce Amyloid-β Deposition in Alzheimer’s Disease
  27. Olfaction in patients with Parkinson’s disease: a new threshold test analysis through turning points trajectories
  28. Remote clinical trials: A timely opportunity for a virtual reality approach and its potential application in neurology
  29. Electrical Stimulation of Injected Muscles to Boost Botulinum Toxin Effect on Spasticity: Rationale, Systematic Review and State of the Art
  30. Comment on “The association between pain and impulse control behaviours in Parkinson's disease”
  31. COVID-19 and related symptoms in patients under disulfiram for alcohol use disorder
  32. Adult attention-deficit/hyperactivity disorder symptoms, cognitive dysfunction and quality of life in high-dose use of benzodiazepine and Z-drug
  33. Smoking-related cue reactivity in a virtual reality setting: association between craving and EEG measures
  34. Pattern of treatment of behavioural and psychological symptoms of dementia and pain: evidence on pharmacoutilization from a large real-world sample and from a centre for cognitive disturbances and dementia
  35. Regulation of microRNAs in Satellite Cell Renewal, Muscle Function, Sarcopenia and the Role of Exercise
  36. Risk of hospitalization associated with benzodiazepines and z‐drugs in Italy: a nationwide multicentre study in emergency departments—comment
  37. Toward a Wearable System for Predicting Freezing of Gait in People Affected by Parkinson's Disease
  38. Selective atrophy of the brachialis muscle in neuralgic amyotrophy: ultrasound imaging of fascicular nerve damage
  39. Vertebral Artery Fenestration Mimicking Acute Dissection
  40. Towards a Redefinition of Cognitive Frailty
  41. Pharmacological treatment of opioid-induced constipation: moving ahead to new targets
  42. Association between Adult Attention Deficit/Hyperactivity Disorder and Intravenous Misuse of Opioid and Benzodiazepine in Patients under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study
  43. Adult Attention-Deficit/Hyperactivity Disorder and Quality of Life in High-Dose Benzodiazepine and Related Z-Drug Users
  44. Editorial: New Advances in Neurorehabilitation
  45. An Indoor Therapeutic Garden for Behavioral Symptoms in Alzheimer’s Disease: A Randomized Controlled Trial
  46. Chemotherapy‐induced peripheral neurotoxicity: A multifaceted, still unsolved issue
  47. Taxane and epothilone‐induced peripheral neurotoxicity: From pathogenesis to treatment
  48. Immune checkpoint inhibitors‐induced neuromuscular toxicity: From pathogenesis to treatment
  49. Platinum‐induced peripheral neurotoxicity: From pathogenesis to treatment
  50. Nerve size correlates with clinical severity in Charcot–Marie–Tooth disease 1A
  51. High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde—reply
  52. Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings
  53. OnabotulinumtoxinA Reduces Temporal Pain Processing at Spinal Level in Patients with Lower Limb Spasticity
  54. Improvement of motor performance in children with cerebral palsy treated with exoskeleton robotic training: A retrospective explorative analysis
  55. High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde
  56. Olfaction and taste in Parkinson’s disease: the association with mild cognitive impairment and the single cognitive domain dysfunction
  57. Non-Aβ-Dependent Factors Associated with Global Cognitive and Physical Function in Alzheimer’s Disease: A Pilot Multivariate Analysis
  58. Intrapretuvalisuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study
  59. Mechanisms of Pain
  60. New Advances in Neurorehabilitation
  61. Neuropsychological testing
  62. MoCA for cognitive screening in Parkinson's disease: Beware of floor effect
  63. The spectrum of Charcot-Marie-Tooth disease due to myelin protein zero: An electrodiagnostic, nerve ultrasound and histological study
  64. Erectile dysfunction and quality of life in men receiving methadone or buprenorphine maintenance treatment. A cross-sectional multicentre study
  65. Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence
  66. Screening for adult attention deficit/hyperactivity disorder in high-dose benzodiazepine dependent patients
  67. Diagnosing mild cognitive impairment in Parkinson’s disease: which tests perform best in the Italian population?
  68. Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia
  69. Determinants of Quality of Life in High-Dose Benzodiazepine Misusers
  70. The burden of chronic pain and the role of neurorehabilitation: consensus matters where evidence is lacking
  71. Pharmacological treatment for familial amyloid neuropathy
  72. Multifocal cognitive dysfunction in high-dose benzodiazepine users: a cross-sectional study
  73. Electrodiagnosis of Lesions of Median and Ulnar Nerve Hand Sensory Branches
  74. The Diagnostic Value of Nerve Ultrasound in an Atypical Palmar Cutaneous Nerve Lesion
  75. Working memory in healthy aging and in Parkinson’s disease: evidence of interference effects
  76. The Italian Consensus Conference on Pain in Neurorehabilitation: rationale and methodology
  77. Psychological Considerations in the Assessment and Treatment of Pain in Neurorehabilitation and Psychological Factors Predictive of Therapeutic Response: Evidence and Recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation
  78. Psychological Treatments and Psychotherapies in the Neurorehabilitation of Pain: Evidences and Recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation
  79. Pathophysiology of Motor Dysfunction in Parkinson’s Disease as the Rationale for Drug Treatment and Rehabilitation
  80. How to diagnose neuropathic pain? The contribution from clinical examination, pain questionnaires and diagnostic tests
  81. An electrodiagnostic technique for assessing palmar proper digital nerves of the hand: Normative data and clinical application
  82. Isolated musculocutaneous nerve injury in a kickboxer
  83. Damage to the Median and Ulnar Nerves After a Snake Bite
  84. Unexpected Inching Explained by an Ulnar Nerve Anatomic Variant Documented by Sonography
  85. Sunderland's median nerve fascicular anatomy revisited by ultrasound
  86. Co-Occurrence of the C9ORF72 Expansion and a Novel GRN Mutation in a Family with Alternative Expression of Frontotemporal Dementia and Amyotrophic Lateral Sclerosis
  87. The Association between Serum Cytokines and Damage to Large and Small Nerve Fibers in Diabetic Peripheral Neuropathy
  88. Screening for Mild Cognitive Impairment in Parkinson’s Disease: Comparison of the Italian Versions of Three Neuropsychological Tests
  89. Cognition and emotional decision-making in chronic low back pain: an ERPs study during Iowa gambling task
  90. Painful Legs and Moving Toes Syndrome: Putative Underlying Pathophysiology as a Hint for Combined Pharmacological Treatment?
  91. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP
  92. Diagnostic and Therapeutic Pitfalls in Considering Chronic Pain as a Disease
  93. Relationship Between Ultrasonographic, Electromyographic, and Clinical Parameters in Adult Stroke Patients With Spastic Equinus: An Observational Study
  94. Effect of 5% Lidocaine Medicated Plaster on Pain Intensity and Paroxysms in Classical Trigeminal Neuralgia
  95. Decision and dopaminergic system: an ERPs study of Iowa gambling task in Parkinson’s disease
  96. Robot-assisted vs. sensory integration training in treating gait and balance dysfunctions in patients with multiple sclerosis: a randomized controlled trial
  97. Periodic thigh pain from radicular endometriosis
  98. Anti-N-Methyl-D-Aspartate Receptor Encephalitis Causing a Prolonged Depressive Disorder Evolving to Inflammatory Brain Disease
  99. Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop
  100. Letter to the Editor
  101. Robot-assisted arm training in patients with Parkinson’s disease: a pilot study
  102. Association between Severe Upper Limb Spasticity and Brain Lesion Location in Stroke Patients
  103. Long-Term Response of Neuropathic Pain to Intravenous Immunoglobulin in Relapsing Diabetic Lumbosacral Radiculoplexus Neuropathy. A Case Report
  104. No evidence of a neuropathic origin in hemiplegic shoulder pain
  105. Neuropathic pain: diagnosis and treatment
  106. Botulinum Toxin Type A Injection Into the Gastrocnemius Muscle for Spastic Equinus in Adults With Stroke
  107. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: a randomised controlled trial
  108. A Randomized, Double Blind, Controlled Trial of Intravenous Immunoglobulins Versus Intravenous Methylprednisolone in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (IMC Study) (S07.001)
  109. Accuracy of botulinum toxin type A injection into the gastrocnemius muscle of adults with spastic equinus: Manual needle placement and electrical stimulation guidance compared using ultrasonography
  110. Abnormalities of intraterritorial and extraterritorial sensory processing in carpal tunnel syndrome and their pathophysiological significance: A comment on the paper by Schmid et al. (Eur J Pain, 2011)
  111. Unilateral fixed mydriasis: an uncommon presentation of temporal lobe epilepsy
  112. P4.20 Pain response to repeated administration of intravenous immunoglobulin in a patient with diabetic lumbosacral radiculoplexus neuropathy. Evidence for proinflammatory cytokine activation
  113. P4.21 The association of ulnar nerve conduction changes with carpal tunnel syndrome. A multivariate analysis study
  114. Immediate versus delayed electrical stimulation boosts botulinum toxin effect: A pilot study
  115. Median Nerve Small- and Large-Fiber Damage in Carpal Tunnel Syndrome: A Quantitative Sensory Testing Study
  116. Central sensitization and sensory symptoms spread in carpal tunnel syndrome: A response to Ginanneschi and Rossiʼs letter on the relationship between central plastic changes and sensory symptoms in peripheral entrapment neuropathies
  117. Guillain-Barré syndrome after short-course efalizumab treatment
  118. Recurrent transitory ischaemic attacks with skin lesions, arthralgia and myalgia should prompt suspicion of atrial myxoma
  119. Central sensitization in carpal tunnel syndrome with extraterritorial spread of sensory symptoms
  120. Muscular pain in Parkinson's disease and nociceptive processing assessed with CO2 laser-evoked potentials
  121. P2.093 Switch from subcutaneous apomorphine to intraduodenal levodopa offers additional beneflt on motor fluctuations and dyskinesias in advanced Parkinson's disease
  122. Intravenous Immunoglobulin for the Treatment of Diabetic Lumbosacral Radiculoplexus Neuropathy
  123. Ulnar nerve impairment at the wrist does not contribute to extramedian sensory symptoms in carpal tunnel syndrome
  124. 132 ULNAR NERVE IMPAIRMENT AT THE WRIST IS NOT CORRELATED WITH EXTRAMEDIAN SPREAD OF SENSORY SYMPTOMS IN CARPAL TUNNEL SYNDROME
  125. Hyperalgesia and laser evoked potentials alterations in hemiparkinson: Evidence for an abnormal nociceptive processing
  126. Pain and motor function in carpal tunnel syndrome
  127. The effect of repetitive transcranial magnetic stimulation on motor performance, fatigue and quality of life in amyotrophic lateral sclerosis
  128. Cingulate Gyrus Tumor Presenting as Panic Attacks
  129. Belly dancer's myoclonus and chronic abdominal pain: Pain-related dysinhibition of a spinal cord central pattern generator?
  130. Proximal pain in patients with carpal tunnel syndrome: a clinical-neurophysiological study
  131. 178 INTRAVENOUS IMMUNOGLOBULINS TREATMENT IMPROVES PAIN IN DIABETIC LUMBOSACRAL RADICULOPLEXUS NEUROPATHY
  132. 215 EXTRAMEDIAN AND PROXIMAL SPREAD OF SENSORY SYMPTOMS IN CARPAL TUNNEL SYNDROME: A CLINICAL-NEUROPHYSIOLOGICAL STUDY
  133. 2.222 Continuous dopaminergic stimulation in advanced PD. Switching from apomorphine to duodopa: Which treatment is better?
  134. FC39.1 The use of intravenous immunoglobulins for the treatment of diabetic lumbosacral radiculoolexus neuropathy
  135. FC19.4 The spread of sensory symptoms outside the median territory in carpal tunnel syndrome indicates the presence of pain-related mechanisms
  136. Extra-median spread of sensory symptoms in carpal tunnel syndrome suggests the presence of pain-related mechanisms
  137. Sensorimotor integration to cutaneous afferents in humans: the effect of the size of the receptive field
  138. Abnormalities of sensory processing and sensorimotor interactions in secondary dystonia: A neurophysiological study in two patients
  139. A case of oligosymptomatic botulism. The role of single-fiber EMG in early diagnosis
  140. Modulation of motor cortex excitability after upper limb immobilization
  141. Enhanced intracortical inhibition in cerebellar patients
  142. Stimulus-response properties of motor system in patients with cerebellar ataxia
  143. Motor Responses to Afferent Stimulation in Juvenile Myoclonic Epilepsy
  144. Abnormal sensorimotor integration is related to disease severity in Parkinson's disease: A TMS study
  145. Abnormal cutaneomotor integration in patients with cerebellar syndromes: a transcranial magnetic stimulation study
  146. Focal hand dystonia after cervical whiplash injury
  147. Changes in motor cortex inhibition over time in patients with amyotrophic lateral sclerosis
  148. Abnormal somatotopic arrangement of sensorimotor interactions in dystonic patients
  149. Different mechanisms contribute to motor cortex hyperexcitability in amyotrophic lateral sclerosis
  150. Hyperexcitable cortical responses in progressive myoclonic epilepsy: A TMS study
  151. Cutaneomotor integration in human hand motor areas: somatotopic effect and interaction of afferents
  152. Transient inhibition of the human motor cortex by capsaicin-induced pain. A study with transcranial magnetic stimulation